Steve Schey
Overview
Explore the profile of Steve Schey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
336
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Popat R, Counsell N, de Tute R, De-Silva D, Phillips E, Cavenagh J, et al.
Br J Haematol
. 2021 Mar;
193(3):e19-e22.
PMID: 33715154
No abstract available.
2.
Fajgenbaum D, Wu D, Goodman A, Wong R, Chadburn A, Nasta S, et al.
Am J Hematol
. 2020 Sep;
95(12):1553-1561.
PMID: 32894785
Idiopathic multicentric Castleman disease (iMCD) is a rare immunologic disorder characterized by systemic inflammation, multicentric lymphadenopathy, and organ dysfunction. Enlarged lymph nodes demonstrate a spectrum of characteristic but variable histopathologic...
3.
Richardson P, Oriol A, Beksac M, Liberati A, Galli M, Schjesvold F, et al.
Lancet Oncol
. 2019 May;
20(6):781-794.
PMID: 31097405
Background: As lenalidomide becomes increasingly established for upfront treatment of multiple myeloma, patients refractory to this drug represent a population with an unmet need. The combination of pomalidomide, bortezomib, and...
4.
Shah S, Ibrahim M, Delaney M, Schey S, Bygrave C, Streetly M, et al.
Clin Kidney J
. 2019 Apr;
12(2):216-223.
PMID: 30976399
Background: Autologous stem cell transplantation (ASCT) and novel therapies have improved the prognosis for patients with multiple myeloma (MM). For those who undergo ASCT while on dialysis, a similar survival...
5.
Schey S, Casado Montero L, Stengel-Tosetti C, Gibson C, Dhanasiri S
Oncol Ther
. 2017 Jul;
5(1):31-40.
PMID: 28680953
Introduction: Lenalidomide is an active agent that was approved for use in the EU in 2015 as a first-line therapy for previously untreated, non-transplant eligible multiple myeloma patients. Our objective...
6.
Maciocia N, Melville A, Cheesman S, Sharpley F, Ramasamy K, Streetly M, et al.
Br J Haematol
. 2017 Feb;
176(6):908-917.
PMID: 28211054
Myeloma patients who become refractory to immunomodulatory agents (IMiDs) and bortezomib have poor survival, with limited therapeutic options. Pomalidomide has shown improved survival and good tolerability in this patient cohort...
7.
Walker I, Coady A, Neat M, Ladon D, Benjamin R, El-Najjar I, et al.
Br J Haematol
. 2016 Oct;
180(3):451-454.
PMID: 27734463
No abstract available.
8.
Parrish C, Morris C, Williams C, Cairns D, Cavenagh J, Snowden J, et al.
Biol Blood Marrow Transplant
. 2016 Feb;
22(6):1009-1016.
PMID: 26827659
The phase III British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X trial (MMX) demonstrated prospectively, for the first time, superiority of salvage autologous stem cell transplantation...
9.
Schey S, Brown S, Tillotson A, Yong K, Williams C, Davies F, et al.
Br J Haematol
. 2015 Apr;
170(3):336-48.
PMID: 25891006
There is a significant unmet need in effective therapy for relapsed myeloma patients once they become refractory to bortezomib and lenalidomide. While data from the front line setting suggest bendamustine...
10.
Moore S, Atwal S, Sachchithanantham S, Streetly M, Khan I, Percy L, et al.
Eur J Haematol
. 2013 Jan;
90(5):420-5.
PMID: 23294279
Objectives: Bortezomib is an effective antimyeloma therapy, but clinical benefits can be limited by neurotoxicity. In newly diagnosed, older patients, modification of the biweekly dosing schedule to weekly regimens improves...